Literature DB >> 35220253

Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.

Martin Svaton1, Marie Drosslerova2, Ondrej Fischer3, Miloslav Marel4, Michal Hrnciarik5, Ondrej Venclicek6, Petr Zuna7, Michal Svoboda8, Jiri Blazek9, Monika Bratova6, Andrea Mullerova3, Bohuslava Vankova10, Daniel Krejci7.   

Abstract

BACKGROUND/AIM: Due to some interconnectedness at the molecular level, this study assessed the possible influence of laboratory parameters associated with systemic inflammatory environment on programmed death-ligand 1 (PD-L1) expression in non-small cell lung carcinoma (NSCLC). PATIENTS AND METHODS: We assessed effects of c-reactive protein (CRP), albumin, haemoglobin, neutrophil, and lymphocyte levels on PD-L1 expression in NSCLC. Patient data were obtained retrospectively from LUCAS, the Czech registry of patients with lung carcinomas. Correlations of two continuous parameters (PD-L1 expression and laboratory parameters) were analysed by correlation coefficient. Differences in continuous parameters between two or more groups were tested by Mann-Whitney or Kruskal-Wallis tests. Independence of two categorical parameters was tested by chi-square test.
RESULTS: We demonstrated no influence of the investigated laboratory parameters on PD-L1 expression in NSCLC, either in continuous or categorical division of variables.
CONCLUSION: Inflammatory laboratory parameters at time of NSCLC diagnosis are unlikely to affect the determination of PD-L1 expression.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  CRP; NLR; NSCLC; PD-L1; albumin; haemoglobin; inflammation; lung cancer

Mesh:

Substances:

Year:  2022        PMID: 35220253     DOI: 10.21873/anticanres.15630

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer.

Authors:  Minehiko Inomata; Masahiro Matsumoto; Isami Mizushima; Zenta Seto; Kana Hayashi; Kotaro Tokui; Chihiro Taka; Seisuke Okazawa; Kenta Kambara; Shingo Imanishi; Toshiro Miwa; Ryuji Hayashi; Shoko Matsui; Kazuyuki Tobe
Journal:  Cancer Diagn Progn       Date:  2022-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.